At the time of writing, BridgeBio Pharma Inc [BBIO] stock is trading at $27.03, up 5.50%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 7.99% over the last week, with a monthly amount drifted -6.15%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, BMO Capital Markets started tracking the stock with Market Perform rating on January 31, 2024, and set its price target to $37. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $58 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating. Citigroup initiated its recommendation with a Buy and recommended $42 as its price target on November 07, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $50. In a note dated July 18, 2023, Jefferies downgraded an Hold rating on this stock and boosted its target price from $24 to $33.
For the past year, the stock price of BridgeBio Pharma Inc fluctuated between $12.75 and $44.32. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $27.03 at the most recent close of the market. An investor can expect a potential drop of -33.41% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
According to BridgeBio Pharma Inc [NASDAQ:BBIO], the company’s sales were 9.30M for trailing twelve months, which represents an -6.68% plunge. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -65.29%, Pretax Profit Margin comes in at -69.95%, and Net Profit Margin reading is -73.08%. To continue investigating profitability, this company’s Return on Assets is posted at -1.24, Equity is 0.53 and Total Capital is -1.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.84 points at the first support level, and at 24.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.21, and for the 2nd resistance point, it is at 29.39.
BridgeBio Pharma Inc [BBIO] reported earnings per share of -$0.96 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.91/share, meaning a difference of -$0.05 and a surprise factor of -5.50%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$1.08 per share as compared to estimates of -$0.82 per share, a difference of -$0.26 representing a surprise of -31.70%.
Ratios To Look Out For
It is important to note that BridgeBio Pharma Inc [NASDAQ:BBIO] has a current ratio of 3.32. As well, the Quick Ratio is 3.32, while the Cash Ratio is 2.61. Considering the valuation of this stock, the price to sales ratio is 543.88.
Transactions by insiders
Recent insider trading involved Scott Randal W., Director, that happened on Mar 01 ’24 when 2500.0 shares were sold. Director, Valantine Hannah completed a deal on Feb 15 ’24 to sell 2915.0 shares. Meanwhile, Director Valantine Hannah sold 2915.0 shares on Jan 16 ’24.
